Cite
HARVARD Citation
Adams, D. et al. (2021). Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet neurology. 20 (1), pp. 49-59. [Online].